Thieler Law Corp, member of the Investor Attorney Network, is investigating whether certain officers and directors of PTC Therapeutics Inc (NASDAQ: PTCT) violated securities laws in connection with certain financial statements.

The investigation seeks to discover if possible claims on behalf of purchasers of the securities of PTC Therapeutics Inc (NASDAQ: PTCT) concerning whether a series of statements by PTC Therapeutics Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On February 23, 2016, PTC Therapeutics Inc revealed receipt of a Refuse to File letter from the United States Food and Drug Administration regarding PTC Therapeutics New Drug Application for the drug Translarna, an oral protein restoration therapy designed to treat a form of muscular dystrophy. The FDA states in the Refuse to File letter that the application was not sufficiently complete to permit a substantive review.

Following this news, NASDAQ: PTCT shares declined more than 55% on intraday trading.

Based in South Plainfield, New Jersey and founded in 1998 PTC Therapeutics Inc is a biopharmaceutical company, engaged in developing and commercializing of drugs that target post-transcriptional control processes.

If you purchased shares of PTC Therapeutics Inc (NASDAQ: PTCT) on or before February 23, 2016, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185